AbbVie Inc. announced positive data from a third late-stage trial ... said a third Phase 3 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson’s disease met its primary ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...

Advancing Light Therapy Research to Enhance Quality of Life for Parkinson's Patients This trial is important becau ...

Parkinson's disease is an illness that affects the part of your brain that controls how you move your body. Some people with Parkinson’s first notice weakness, difficulty walking, and stiff muscles.